Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261349 | 0.94 | NAMPT (0.36) | NAMPTSIGMAR1TIPARPBMPR1BBMPR1A | |
| SCHEMBL9256115 | 0.85 | SIGMAR1 (0.40) | NAMPTSIGMAR1TIPARP | |
| SCHEMBL9256107 | 0.82 | SIGMAR1 (0.40) | NAMPTSIGMAR1TIPARP | |
| SCHEMBL9252075 | 0.80 | HRH3 (0.44) | NAMPT | |
| SCHEMBL9261326 | 0.76 | FFAR4 (0.33) | NAMPTSIGMAR1CYP2C9CYP2C19 | |
| SCHEMBL9257345 | 0.76 | FFAR4 (0.33) | NAMPTSIGMAR1CYP2C9CYP2C19 | |
| SCHEMBL9256008 | 0.74 | DPP8 (0.40) | NAMPTTIPARP | |
| SCHEMBL9252901 | 0.72 | DPP8 (0.41) | NAMPTTIPARP | |
| SCHEMBL7878390 | 0.71 | MITF (0.43) | NAMPTSIGMAR1TIPARPCYP2C9CYP2C19 | |
| SCHEMBL256354 | 0.68 | SIGMAR1 (0.46) | NAMPTSIGMAR1TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | NAMPT 1564/4885SIGMAR1 1154/4885TIPARP 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.